These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 10499824)

  • 1. Prevention of hypercalcaemic nephropathy and tissue calcification by glucagon during phosphate infusion.
    Condon JR; Cross JA; Yones A
    Med Hypotheses; 1999 Jul; 53(1):45-7. PubMed ID: 10499824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular calcification in patients with end-stage renal disease.
    Floege J; Ketteler M
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V59-66. PubMed ID: 15284362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffuse calcinosis and intradermal tophi in a uremic pateint: effect of low-calcium hemodialysis and mechanism of hypercalcemia.
    Hsu SC; Lee YY; Wang MC; Liu HL; Cheng MF; Huang JJ
    Blood Purif; 2004; 22(2):224-8. PubMed ID: 15044822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical treatment of hypercalcemia.
    Schaiff RA; Hall TG; Bar RS
    Clin Pharm; 1989 Feb; 8(2):108-21. PubMed ID: 2521820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density.
    Asmus HG; Braun J; Krause R; Brunkhorst R; Holzer H; Schulz W; Neumayer HH; Raggi P; Bommer J
    Nephrol Dial Transplant; 2005 Aug; 20(8):1653-61. PubMed ID: 15930018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fetuin-A (AHSG) prevents extraosseous calcification induced by uraemia and phosphate challenge in mice.
    Westenfeld R; Schäfer C; Smeets R; Brandenburg VM; Floege J; Ketteler M; Jahnen-Dechent W
    Nephrol Dial Transplant; 2007 Jun; 22(6):1537-46. PubMed ID: 17389622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of nocturnal compared with conventional hemodialysis on mineral metabolism: A randomized-controlled trial.
    Walsh M; Manns BJ; Klarenbach S; Tonelli M; Hemmelgarn B; Culleton B
    Hemodial Int; 2010 Apr; 14(2):174-81. PubMed ID: 20041960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
    Mason MA; Shepler BM
    Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Control of calcium and phosphate metabolism and prevention of vascular calcifications in uremic patients].
    Malberti F; Ravani P
    G Ital Nefrol; 2005; 22 Suppl 31():S47-52. PubMed ID: 15786402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic associations of serum calcium, phosphate and calcium phosphate concentration product with outcomes in kidney transplant recipients.
    Schaeffner ES; Födinger M; Kramar R; Sunder-Plassmann G; Winkelmayer WC
    Transpl Int; 2007 Mar; 20(3):247-55. PubMed ID: 17291218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of lowering dialysate calcium concentration on serum bone turnover markers in hemodialysis patients.
    Hamano T; Oseto S; Fujii N; Ito T; Katayama M; Horio M; Imai E; Hori M
    Bone; 2005 May; 36(5):909-16. PubMed ID: 15794928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Can cardiovascular calcifications be prevented in chronic kidney disease?].
    Coen G; Manni M; Mantella D; Splendiani G
    G Ital Nefrol; 2006; 23 Suppl 34():S21-5. PubMed ID: 16633990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Arteriosclerosis and vascular calcification in chronic kidney disease (CKD) patients].
    Masho Y; Shigematsu T
    Clin Calcium; 2007 Mar; 17(3):354-9. PubMed ID: 17339739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between serum calcium and phosphate levels and cardiac valvular procedures in the hemodialysis population.
    Rubel JR; Milford EL
    Am J Kidney Dis; 2003 Feb; 41(2):411-21. PubMed ID: 12552504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of hypercalcaemic syndrome in tumour patients, especially with mithramycin].
    Senn HJ; Peyer P
    Dtsch Med Wochenschr; 1978 Jan; 103(3):101-7. PubMed ID: 146599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The requirement of low calcium dialysate in patients on continuous ambulatory peritoneal dialysis receiving calcium carbonate as a phosphate binder.
    Cheng IK; Lu HB; Chan CY; Cheng SW; Robinson JD; Tam SC; Lo WK; Cheung WC
    Clin Nephrol; 1993 Aug; 40(2):100-5. PubMed ID: 8222365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Calcitonin and glucagon secretion in active nephrolithiasis].
    Kuczera M; Kiersztejn M; Kokot F
    Z Gesamte Inn Med; 1987 Apr; 42(8):209-12. PubMed ID: 3630289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of alkaline calcium salts as phosphate binder in uremic patients.
    Fournier A; Morinière P; Ben Hamida F; el Esjer N; Shenovda M; Ghazali A; Bouzernidj M; Achard JM; Westeel PF
    Kidney Int Suppl; 1992 Oct; 38():S50-61. PubMed ID: 1405382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of dialysate calcium concentration in hemodialysis.
    Toussaint N; Cooney P; Kerr PG
    Hemodial Int; 2006 Oct; 10(4):326-37. PubMed ID: 17014507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.